These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 24821550

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A, Sesoko S, Nakashima M, Hayashi N, Taniguchi A, Horie Y, Graefe-Mody EU, Woerle HJ, Dugi KA.
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [Abstract] [Full Text] [Related]

  • 4. Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury.
    Terawaki Y, Nomiyama T, Kawanami T, Hamaguchi Y, Takahashi H, Tanaka T, Murase K, Nagaishi R, Tanabe M, Yanase T.
    Cardiovasc Diabetol; 2014 Nov 19; 13():154. PubMed ID: 25407968
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.
    Graefe-Mody EU, Padula S, Ring A, Withopf B, Dugi KA.
    Curr Med Res Opin; 2009 Aug 19; 25(8):1963-72. PubMed ID: 19552619
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice.
    Chen L, Klein T, Leung PS.
    Curr Mol Med; 2012 Sep 19; 12(8):995-1004. PubMed ID: 22804249
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The DPP-IV inhibitor linagliptin and GLP-1 induce synergistic effects on body weight loss and appetite suppression in the diet-induced obese rat.
    Hansen HH, Hansen G, Paulsen S, Vrang N, Mark M, Jelsing J, Klein T.
    Eur J Pharmacol; 2014 Oct 15; 741():254-63. PubMed ID: 25160746
    [Abstract] [Full Text] [Related]

  • 16. Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356)--investigations in DPP-4 deficient and wildtype rats.
    Retlich S, Withopf B, Greischel A, Staab A, Jaehde U, Fuchs H.
    Biopharm Drug Dispos; 2009 Nov 15; 30(8):422-36. PubMed ID: 19771584
    [Abstract] [Full Text] [Related]

  • 17. Significance of vascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats.
    Takai S, Sakonjo H, Jin D.
    J Pharmacol Sci; 2014 Nov 15; 125(4):386-93. PubMed ID: 25030743
    [Abstract] [Full Text] [Related]

  • 18. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ.
    J Am Pharm Assoc (2003); 2009 Nov 15; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.